In a commentary published on PubMed Central, researchers reviewed two clinical trials suggesting that a single 25 mg dose of psilocybin may produce rapid antidepressant effects in treatment-resistant depression by engaging the brain’s 5-HT2A serotonin receptors. The review is a commentary on existing trials, not a new trial itself. Key takeaways Rapid onset: The Goodwin […]
A 2024 systematic review pooled 20 studies and 2,959 participants to assess how psilocybin affects thinking. Results were mixed: global cognition and processing speed were largely unchanged in healthy adults, while patients with treatment-resistant depression showed some improvements in attention, working memory, and emotional processing. Key takeaways Global cognition held steady in healthy volunteers across […]
The FDA announced a package of measures designed to speed up clinical research into psychedelic-based treatments for serious conditions including treatment-resistant depression, PTSD, and substance use disorders. The agency acted following a Trump executive order, and explicitly noted that fast-tracking research does not constitute drug approval or a finding of safety and effectiveness. Key takeaways […]
A post hoc path analysis of 79 patients with treatment-resistant depression has found that what happens inside the psilocybin session, specifically the quality of the psychedelic experience, predicts antidepressant outcomes more strongly than the therapeutic alliance formed before dosing. The study, published in July 2026 and drawing on existing trial data, used path analysis to […]
A new open-label trial published in June 2026 offers some of the most encouraging data yet on psilocybin-assisted therapy veterans living with treatment-resistant depression. According to the study, a single oral dose of 25 milligrams of psilocybin was associated with a 59 percent reduction in anxiety scores at three weeks, and those improvements in anxiety, […]
A narrative review published in Schizophrenia Research in 2026 takes on one of psychiatry’s most stubborn frontiers: the negative and depressive symptoms of schizophrenia spectrum disorder. These are not the dramatic features that dominate popular imagination. They are the quiet, grinding ones, flattened affect, social withdrawal, loss of motivation, and depressive states that current antipsychotic […]